Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1971-1980 Newer>

The Motley Fool April 28, 2005 Stephen D. Simpson	Glaxo Works to Stay on Track With FDA issues near resolution, Glaxo should continue its respectable growth trajectory. Investors looking at the pharmaceutical space would do well to at least consider this stock.
The Motley Fool April 28, 2005 Brian Gorman	PPD Branches Out The company, which concentrates on running clinical trials for pharmaceutical and biotech clients is right in diversifying, but its strategy carries its own risk.
The Motley Fool April 28, 2005 Stephen D. Simpson	Bristol-Myers: Hang in There Generics are wreaking havoc on growth, but patient investors can pin hopes on drugs now in the pipeline.
The Motley Fool April 27, 2005 Stephen D. Simpson	Becton, Dickinson's Boring Reliability This broadly diversified medical device company doesn't grow fast, but it is consistent. Investors looking for a stable and dependable company with broad exposure to the medical industry should take a look for themselves at Becton, Dickinson.
The Motley Fool April 27, 2005 Charly Travers	Vertex's Emerging Pipeline Early-stage drugs, including one for hepatitis C, are moving forward. For Vertex investors, the phase 2 trials will be the story to watch over the next two years.
The Motley Fool April 27, 2005 Brian Gorman	Cautious on Medco Medco's earnings were respectable, but for now investors may want to step back.
The Motley Fool April 27, 2005 Tim Hanson	Quest for Value and Growth Quest Diagnostics, a consistent winner, could be good medicine for your portfolio.
The Motley Fool April 27, 2005 Charly Travers	Thanks for the Ride, Transkaryotic Selling was the right move, but it's hard to let go of stocks you like. Transkaryotic has certainly done very well for its shareholders.
The Motley Fool April 27, 2005 Stephen D. Simpson	VCA Antech Sure Can Fetch Same-store sales growth and margin improvements drive another good quarter for the veterinary care provider. Long-term investors will likely see themselves well rewarded over time, but they shouldn't kid themselves about the risks.
The Motley Fool April 26, 2005 Stephen D. Simpson	Growth Is Knee-High Zimmer turns in another fine quarter, with strength in knee implants leading the way.
<Older 1971-1980 Newer> Return to current articles.